Hybridan Small Cap Feast

Joiners: No joiners today.  

Leavers: Meggitt Plc has left the Main Market. 

Banquet Buffet

Artisanal Spirits 74p  £51.6m (ART.L)

The curators of single-cask and limited-edition whisky and owner of The Scotch Malt Whisky Society (SMWS), announces its results for the six months ended 30 June 2022. Revenue increased 25% to £9.9m (H1-21: £7.9m) with growth in UK venues, Europe and China. EBITDAE loss was £0.3m (H1 21: profit of £0.2m) following planned ongoing investment for growth. With continued growth in global SMWS membership to over 36,000, the company indicates that it remains on track to deliver a doubling of revenue from 2020 to 2024.

Epwin Group  73p  £105.8m (EPWN.L)

The  manufacturer of energy efficient and low maintenance building products for the Repair, Maintenance and Improvement (RMI), new build and social housing sectors, announces its unaudited results for the six months to 30 June 2022. Revenue was £178m, up 12.3% year-on-year. Underlying operating profit margin was maintained at 6% with pricing actions and surcharges. Covenant net debt reduced to £7.3m, down from £9.4m at the end of 2021. The Board is confident in achieving the 2022 result in line with its expectations. 

Gateley (Holdings) 187.5p  £233.5m (GTLY.L)

The legal and professional services group announces that it has paid consideration of £100k in cash, pursuant to the terms of the acquisition of Tozer Gallagher announced on 23 July 2021. As previously announced each recipient has applied 50% of the consideration to subscribe for ordinary shares of 10p each in the capital of Gateley and a total of 25,071 ordinary shares have been issued in satisfaction of this subscription. The company now has a total of 124,618,605 ordinary shares in issue with one voting right per share.

ImmuPharma 4.4p  £14.8m (IMM.L)

The specialist drug discovery and development company announces that, further to the Company’s notification of 7 July 2022, its US partner for Lupuzor™ (P140), Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA) to the Type C meeting. The FDA response was detailed and included significant guidance on next steps for the clinical programme. This included advice on the dosing regime. The FDA also provided guidance on the study protocol that can be amended to improve the regulatory outcome. ImmuPharma is currently reviewing the written response with Avion and will make a further notification in due course.

Itaconix  5.9p  £26.6m (ITX.L)

The innovator in sustainable plant-based polymers to decarbonise everyday consumer products, announces its unaudited interim results for the six months ended 30 June 2022. Revenues increased 124% year-on-year to $3.1m. Adjusted EBITDA was a loss of $0.6m (H1 21: loss of $0.7m). The company remains on course to deliver full year 2022 revenues ahead of current market expectations. Adjusted EBITDA loss for full year 2022 is expected to improve from 2021, but below previous market expectations, reflecting continued investment in growth.

ITM Power 111.3p  £683m (ITM.L)

The energy storage and clean fuel group, announces final results for the year ended 30 April 2022. Revenue was £5.6m, up 30% from the previous year. The revenue from the 24MW Leuna project was not recognised in the year. Adjusted EBITDA loss widened to £39.8m (FY21: loss of £21.4m). Cash balance was £365.9m (FY21: £176.1m). The guidance for FY23 is: product revenue of £23-28m (with 48-65 MW delivered) and adjusted EBITDA loss of £45-50m. Contracts backlog as at September 2022 increased by 79% YoY to 755 MW.

Mosman Oil and Gas 0.06p  £3.1m (MSMN.L)

The oil exploration, development, and production company with projects in the U.S. and Australia, announces that the Cinnabar-1 well in Tyler County, Texas is expected to commence drilling in approximately 7 days. Mosman owns a c.75% working interest in the well. Mosman Operating LLC, a 100% owned subsidiary of Mosman, is the operator of the lease.

Pharos Energy 24.4p  £106.9m (PHAR.L)

The independent oil and gas exploration and production company, announces its interim results for the six months ended 30 June 2022. Revenue was $129.6m prior to hedging losses of $17.3m (H1 21: $72.9m prior to hedging losses of $13.7m). Operating profit (including impairments) was £110.2m, up 260% year-on-year. Net cash was $9.6m compared to a net debt of $4.5m in H121. The company’s working interest production guidance remains unchanged at 6,350 – 7,800 boepd ne for 2022 full year and plans to recommence dividends no later than mid-2023.

TransGlobe Energy 265p  £199m (TGL.L)

The oil exploration and production company announces that the leading proxy advisor, Institutional Shareholder Services (ISS) recommends institutional investors to vote for the proposed business combination of TransGlobe and VAALCO Energy at TransGlobe’s special meeting of the shareholders. ISS’s recommendations are in line with the TransGlobe Board of Directors’ unanimous approval of the proposed business combination which creates a world-class African-focused E&P company.

XLMedia 33p  £86.6m (XLM.L)

The global digital publisher, connecting advertisers with consumers, announces an expanded partnership with Advance Local to create premium betting content and a new revenue stream for their MassLive.com brand, a leading Massachusetts news and information website attracting an average of 6.5m unique visitors every month. MassLive.com represents the second Advance Local property with which XLMedia has partnered. The first one was cleveland.com and XLMedia has helped fuel cleveland.com’s growth in the sports betting segment since February 2022.

*A corporate client of Hybridan LLP

** Content not provided by Hybridan LLP

This document has been prepared by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).